| Literature DB >> 34117435 |
Simon J Littlewood1, Oyku Dalci2, Calogero Dolce3, L Shannon Holliday4, Sasan Naraghi5.
Abstract
Orthodontic retention remains one of the great challenges in orthodontics. In this article, we discuss what is on the horizon to help address this challenge, including biological approaches to reduce relapse, treating patients without using retainers, technological developments, personalised medicine and the impact of COVID-19 on approaches to orthodontic retention.Entities:
Year: 2021 PMID: 34117435 PMCID: PMC8193167 DOI: 10.1038/s41415-021-2937-8
Source DB: PubMed Journal: Br Dent J ISSN: 0007-0610 Impact factor: 1.626
Fig. 1New biological approaches to retention. a) Sclerostin is a protein released by osteocytes and cells of the periodontal ligament, which blocks the maturation of pre-osteoblasts into bone-forming osteoblasts. Pre-osteoblasts also express RANKL, which can stimulate osteoclasts to resorb bone. Sclerostin also regulates mineralisation by late osteoblasts. Therefore, blocking sclerostin activity using romosozumab, a humanised monoclonal antibody that inhibits sclerostin, stimulates bone formation. b) Stimulation of RANK on the osteoclast surface by RANKL is essential for osteoclast formation and bone resorption. RANK is also packaged into extracellular vesicles (EVs) and released by osteoclasts. These RANK-EVs can interact with RANKL to competitively inhibit the interaction between RANKL and RANK on the osteoclast surface. In addition, when RANK-EVs interact with RANKL proteins on the pre-osteoblast surface, they stimulate a RANKL reverse signalling pathway that promotes bone formation